Bolt Biotherapeutics, Inc. (BOLT) stock
Close on Nov 11, 2026Market cap $12.06MP/E –Yield –
Bolt Biotherapeutics, Inc. grew revenue 12.8% to $4.70M over the twelve months to Jun 30, 2026. Free cash flow was -$39.92M. At the latest close the market valued the company at $12.06M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.06M
- P/E ratio
- –
- Price to sales
- 2.57
- Price to book
- 0.95
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.70M
- Net income
- -$28.74M
- EPS, diluted
- -$16.44
- Free cash flow
- -$39.92M
- Book value per share
- $7.48
- Diluted shares
- 2M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $6.30
- Open
- $6.38
- Day's range
- $6.18 – $6.38
- Volume
- 42,676
- Average volume (20 days)
- 738,012
- Beta (5 years)
- 0.64
- 52-week range
- $3.10 – $7.78
- RSI (14 days)
- 63.0
- Volatility (1 year)
- 88.3%
- Relative volume
- 0.23×
- WACC
- 8.1%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BOLT | S&P 500 | Difference | BOLT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +52.3% | -2.4% | +54.7 pts | ||
| 3 months | +57.3% | -1.2% | +58.4 pts | ||
| Year to date | +14.5% | +12.3% | +2.2 pts | ||
| 1 year | +30.1% | +12.4% | +17.7 pts | ||
| 3 years | -67.7% | +78.8% | −146.5 pts | -31.4% | +21.4% |
| 5 years | -97.0% | +75.2% | −172.1 pts | -50.3% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bolt Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- Results
About Bolt Biotherapeutics
Pharmaceutical Preparations
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on developing cancer treatments by engaging the innate immune system. Utilizing its proprietary Boltbody Immune-Stimulating Antibody Conjugate platform, the company combines tumor-targeting antibodies with immune-stimulating linker-payloads to generate anti-tumor immune responses. Its lead clinical product candidate, BDC-4182, targets claudin 18.2 for the treatment of gastric and gastroesophageal junction cancers. Additionally, its pipeline includes preclinical programs such as a CEA-targeted ISAC, a PD-L1-targeted ISAC, and BDC-3042, an agonist antibody targeting dectin-2 to repolarize tumor-associated macrophages. The company operates in the biopharmaceutical research and development space, engaging with industry partners and academic institutions.
Company profile, executives and historyBolt Biotherapeutics stock: common questions
What is Bolt Biotherapeutics's stock price?
BOLT closed at $6.26 on Nov 11, 2026, down 0.63% on the day. Over the past 52 weeks it traded between $3.10 and $7.78.
What is Bolt Biotherapeutics's market cap?
Bolt Biotherapeutics was worth $12.06M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BOLT's P/E ratio?
Bolt Biotherapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$16.44), so it has no meaningful P/E ratio.
How much revenue does Bolt Biotherapeutics make?
Bolt Biotherapeutics reported revenue of $4.70M for the twelve months to Jun 30, 2026, up 12.8% from a year earlier.
Does Bolt Biotherapeutics pay a dividend?
No. Bolt Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Bolt Biotherapeutics report earnings next?
Bolt Biotherapeutics is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BOLT stock performed over the past year?
Including dividends, BOLT returned +30.1% over the past year, against +12.4% for the S&P 500.
How many BOLT shares are sold short?
0M shares were sold short at the latest FINRA report, 3.85% of the float, or 1.0 days of average trading volume.
Who are Bolt Biotherapeutics's competitors?
Companies most similar to Bolt Biotherapeutics by business, industry and size include IMNM, WHWK, MRKR, XBIO, HCWB.
See a number that looks wrong?